<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01084889</url>
  </required_header>
  <id_info>
    <org_study_id>pfm 10k001 TiLOOP® Total 6</org_study_id>
    <nct_id>NCT01084889</nct_id>
  </id_info>
  <brief_title>Anterior Pelvic Prolapse Reconstruction With TiLOOP® Total 6</brief_title>
  <official_title>National, Multicentre Post-marketing Surveillance Study on Anterior Pelvic Prolapse Reconstruction With Titanium-coated Polypropylene Mesh (TiLOOP® Total 6)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>pfm medical ag</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aix Scientifics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GfE Medizintechnik GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>pfm medical titanium gmbh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayes GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Crolll Gmbh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>pfm medical ag</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the influence of Anterior Pelvic Prolapse
      Reconstruction with a titanised polypropylene mesh on rate of erosion and patients quality of
      live.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicentre, non-randomised, observational clinical device investigation will be
      performed to obtain post-marketing information on the TiLOOP® pelvic floor reconstruction
      meshes and in particular on the rate of rare erosions of the device under investigation as
      well as on the improvement of patients' quality of life. It is expected that the rate of
      erosions is equal or lower compared to competitor devices currently on the market. To verify
      this, it will be shown that within the first year the erosion rate found for the product
      under investigation is in the range of 7.9 ± 5.4 %, which is the mean erosion rate found in
      the recent literature. Erosion, in the sense of the hypothesis, is any erosion 1 requiring
      more than simply the cut off of a single short filament.

      It is also expected that the patient's quality of life is meliorated after implantation of a
      TiLOOP® Total 6 mesh. To verify this, it will be shown that by means of a validated
      questionnaire the subjective quality of life after 6 months is significantly better than
      before implantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2010</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Erosion rate</measure>
    <time_frame>12 months</time_frame>
    <description>Erosion, in the sense of the end point, is any erosion requiring more than simply the cut off of a single short filament.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>It will be shown that by means of a validated questionnaire whether the subjective quality of life after 6 months is significantly better than before implantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>at 6, 12, 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the mesh implantation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erosion rate</measure>
    <time_frame>36 months</time_frame>
    <description>Erosion, in the sense of the end point, is any erosion requiring more than simply the cut off of a single short filament.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's quality of life</measure>
    <time_frame>12 and 36 months</time_frame>
    <description>It will be shown that by means of a validated questionnaire whether the subjective quality of life after 6 months is significantly better than before implantation.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">292</enrollment>
  <condition>Cystocele</condition>
  <condition>Uterine Prolapse</condition>
  <arm_group>
    <arm_group_label>symptomatic genital descensus</arm_group_label>
    <description>Women with a symptomatic genital descensus : at least stage II (ICS-classification according pelvic organ prolapse quanification (POP-Q) system), or stage I with a symptomatic requiring intervention.
Standard method to implant the TiLOOP® Total 6 surgical mesh transvaginally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TiLOOP® Total 6 (Surgical mesh implantation)</intervention_name>
    <description>The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans vaginal by the aid of surgical instruments to place the mesh arms.</description>
    <arm_group_label>symptomatic genital descensus</arm_group_label>
    <other_name>TiLOOP® Total 6</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with a symptomatic genital descensus treated in the center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with a symptomatic genital descensus : at least stage II (ICS-classification
             according POP-Q system), or stage I with a symptomatic requiring intervention. This
             applies to primary as well as recurrent intervention

          -  Existence of a cystocele.

          -  Patient is mentally able to understand the nature, aims, or possible consequences of
             the clinical investigation

          -  Patient information has been handed out and all written consents are at hand.

          -  Patient has attained full age.

        Exclusion Criteria:

          -  Pregnancy or unfinished family planning.

          -  Known intolerance to the mesh-implants under investigation.

          -  Patients with acute (last 12 months) carcinoma.

          -  Patients with history of radiotherapy in the pelvic area.

          -  Genital descensus without any complaints.

          -  Patients with implanted pelvic floor mesh.

          -  Systemic steroid treatment.

          -  Lack of written patients' informed consent.

          -  Lack of patient compliance regarding data collection, treatment or follow-up
             investigations in the scope of the protocol.

          -  Patient is institutionalised by court or official order (MPG §20.3).

          -  Participation in another clinical investigation.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Fünfgeld, Dr. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik Tettnang GmbH, Tettnang</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Berliner Kontinenzzentrum am Franziskus Krankenhaus,</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Dresden- Friedrichsstadt</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Diakoniekrankenhaus Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Krankenhaus Leipzig,</name>
      <address>
        <city>Leipzig</city>
        <zip>04277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionale Kliniken Holding RKH GmbH, Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beckenbodenzentrum München</name>
      <address>
        <city>München</city>
        <zip>81679</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Tettnang GmbH</name>
      <address>
        <city>Tettnang</city>
        <zip>88069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oberlausitzer Bergland gGmbH,</name>
      <address>
        <city>Zittau</city>
        <zip>02763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Farthmann J, Mengel M, Henne B, Grebe M, Watermann D, Kaufhold J, Stehle M, Fuenfgeld C. Improvement of pelvic floor-related quality of life and sexual function after vaginal mesh implantation for cystocele: primary endpoint of a prospective multicentre trial. Arch Gynecol Obstet. 2016 Jul;294(1):115-21. doi: 10.1007/s00404-016-4014-0. Epub 2016 Jan 18.</citation>
    <PMID>26781262</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2010</study_first_submitted>
  <study_first_submitted_qc>March 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2010</study_first_posted>
  <last_update_submitted>June 22, 2017</last_update_submitted>
  <last_update_submitted_qc>June 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>polypropylene mesh</keyword>
  <keyword>Prolapse</keyword>
  <keyword>Cystocele</keyword>
  <keyword>Surgical Mesh</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Cystocele</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

